Dr Philippe RONDEAUX Chef de Clinique RHUMATOLOGIE ISPPC

Slides:

Advertisements

Similar presentations

‘Arthritis’ nomenclature in the daily practice Luc De Clercq, MD.

Advertisements

Understanding the Immune System

Immunotherapy K J. Goodrum Immunotherapies Vaccines (toxoid, attenuated live, killed cell vaccines, subcellular, DNA, peptide) Adjuvants (nonspecific.

The Role of Aryl Hydrocarbon Receptor (AhR) in the Immune System of Aging Mice Duy Pham Dr. Nancy I. Kerkvliet Department of Environmental and Molecular.

Abrar M. Radwan Saleh Dr. Adham Abo-Taha An-Najah National University College of Pharmacy Pharmacy Program: Pharm D.

Patent issue. Currently known to causes apoptotic cell death, cellular proliferation, differentiation, inflammation, and viral replication promoting.

Figure 1. Mechanism of migration of leucocytes from peripheral blood into inflamed tissues. Selectins ICAM-1 CD11a/CD18 CD11b/CD18 Chemokines: MCP-1 Chemotaxins:

Inflammation Due To RA.

( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.

BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.

Immune responses that are inadequately controlled, inappropriately targeted to host tissues, or triggered by commensal microorganisms or usually harmless.

Lecture 6 clinical immunology Cytokines

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

ARTHRITIS Rheumatoid Arthritis Presented By: Ali Raza Ansar Qudsia Sehar Hafsa Kabir Rheumatoid Arthritis Presented By: Ali Raza Ansar Qudsia Sehar Hafsa.

Advances in the Treatment of Crohn’s Disease GASTROENTEROLOGY 2004;126:1574–1581.

Page 1 What is TNFWhat is TNF? --Creative BioMart.

Mathematical Modeling of Immunopathogenesis of Rheumatoid Arthritis

Cytokines: Introduction

Introduction to pathology

Early intervention with Interleukin-1 Receptor Antagonist Protein modulates catabolic microRNA and mRNA expression in cartilage after impact injury A.A.

Hal M. Hoffman, MD, Lori Broderick, MD, PhD

Monoclonal antibodies and fusion proteins in medicine

MOnoclonal antibodies and potential applications in migraine

The Biochemistry of Rheumatoid Arthritis

My Treatment Approach to Rheumatoid Arthritis

Ixekizumab Drugbank ID : DB11569 Molecular Weight (Daltons) :146,158

Biologic therapy of inflammatory bowel disease

What are the effector pathways, transcriptional regulators and activators of synovial tissue macrophages in healthy donors and in patients with RA in remission?

Signal Transduction: Gain of Activin Turns Muscle into Bone

Figure 1 Structure of TNF antagonists

My Treatment Approach to Rheumatoid Arthritis

Figure 4 Simplified T cell and antigen presenting

Figure 3 Proposed mechanisms underlying the links

Anti-inflammatory effect of low intensity ultrasound (LIUS) on complete Freund's adjuvant-induced arthritis synovium J.-I. Chung, S. Barua, B.H. Choi,

Early intervention with Interleukin-1 Receptor Antagonist Protein modulates catabolic microRNA and mRNA expression in cartilage after impact injury A.A.

The Leptin Connection: Regulatory T Cells and Autoimmunity

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases.

IL-6 pathway in the liver: From physiopathology to therapy

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Biologic therapy of inflammatory bowel disease

New class of anti-inflammatory agents for colonic epithelial cells

CLA-1/SR-BI protein may promote cholesterol removal from peripheral cells Figure 84 The CLA-1 receptor is the human homolog of the SR-I receptor in mice.

Roles for Chemokines in Liver Disease

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Hal M. Hoffman, MD, Lori Broderick, MD, PhD

Figure 4 Macrophage-targeting antitumour treatment approaches

Identifying and Treating COPD in Cardiac Patients

Yiping Wang, Yuet-Ching Tay, David C.H. Harris Kidney International

RA also increases the risk for work disability and therefore impacts livelihood. The percentage of RA patients who quit working after only.

Biological Therapies for Inflammatory Bowel Diseases

Anti-inflammatory effect of low intensity ultrasound (LIUS) on complete Freund's adjuvant-induced arthritis synovium J.-I. Chung, S. Barua, B.H. Choi,

B-Cell-Directed Therapy for Inflammatory Skin Diseases

Roles for the interleukin-4 receptor and associated JAK/STAT proteins in human articular chondrocyte mechanotransduction S.J. Millward-Sadler, Ph.D.,

L’antagoniste se lie à Blys

Volume 140, Issue 2, Pages e4 (February 2011)

High Invasive Melanoma Cells Induce Matrix Metalloproteinase-1 Synthesis in Fibroblasts by Interleukin-1α and Basic Fibroblast Growth Factor-Mediated.

Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney Yee-Yung Ng, Chun-Cheng Hou, Wansheng.

Wenjun Ouyang, Anne O’Garra Immunity

Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microgliaIncreasing concentrations of ADP (5, 50, and 200 μM) increased tumor.

Figure 4 Role of chemokines in dendritic cell migration

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Immunoregulatory role of TNFα in inflammatory kidney diseases

Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments László Maródi, MD, PhD, Jean-Laurent.

Molecular and cellular mechanisms of allergic disease

Figure Simple schematic depicting the general effects of selected DMTs on lymphocytes Simple schematic depicting the general effects of selected DMTs on.

Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases Susan Lee, MD, Mark Ballow, MD Journal of.

Schematic representation of the balance between pro- and anti-inflammatory cytokines elicited during bacterial sepsis. Schematic representation of the.

Signal Transduction: Gain of Activin Turns Muscle into Bone

Presentation transcript:

Dr Philippe RONDEAUX Chef de Clinique RHUMATOLOGIE ISPPC CHU de CHARLEROI

Alerte Arthrose LeVif/l'Express no. 37 | 15 septembre 2017

Arthrose vs Arthrite

Arthrose vs Arthrite

Arthrose vs Arthrite

Arthrose

Arthrose : Prévalence

Arthrose

Arthrose : évolution

Arthrose : Prise en Charge

Arthrose : Prise en Charge

Sport et Arthrose

La Polyarthrite Rhumatoïde

La Polyarthrite Rhumatoïde

La Spondylarthrite ankylosante

La Spondylarthrite ankylosante

Physiopathologie de la Spondylarthrite ankylosante

Polyarthrite Psoriasique

Role du TNFalpha dans l’Inflamation

Inhibition des cytokines Interaction normale Neutralisation des cytokines Cytokines inflammatoires Anticorps monoclonal Récepteur de cytokine Récepteur soluble Signaux inflammatoires Pas de signal Bloquage du récepteur Anticorps monoclonal Inhibition of Cytokines Cytokines exert their damaging effects by binding to specific receptors, and there are several potential approaches that can be employed to block these effects. Cytokines can be neutralized through the use of antibodies or soluble receptors. With this approach, the cytokine never reaches the receptor on the cell of interest. This avenue for the treatment of RA has been taken with soluble TNF- receptor fusion proteins, soluble IL receptors, monoclonal antibodies against TNF-, and monoclonal antibodies against IL-6. Receptor antagonists or antibodies can bind to cytokine receptors on cells and prevent cytokines from binding. This blocks their actions on the cell in question. This approach to the treatment of RA has been taken with recombinant IL-1Ra and an antibody against the IL-6 receptor. Administration of anti-inflammatory cytokines can inhibit expression of inflammatory cytokines. This approach has been taken with IL-4 and IL-10. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-916. Antagoniste du récepteur Pas de signal Adapté avec la permission de Choy EHS, Panayi GS. N Engl J Med 2001;344:907-916. Copyright © 2001 Massachusetts Medical Society. All rights reserved.

Maladies concernées par le TNFα Polyarthrites Spondylarthrites Rhumatisme Psoriasiques

Ostéoporose

Ostéoporose fracturaire

Ostéoporose vs Arthrose

Ostéoporose : diagnostique

Physiopathologie de l’Ostéoporose

Ostéoporose : traitements

La Fibromyalgie

La Fibromyalgie